rs59385968
Variant names:
Variant summary
Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_021098.3(CACNA1H):c.6939C>T(p.Pro2313Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00171 in 1,612,694 control chromosomes in the GnomAD database, including 48 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.0088 ( 28 hom., cov: 33)
Exomes 𝑓: 0.00097 ( 20 hom. )
Consequence
CACNA1H
NM_021098.3 synonymous
NM_021098.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.107
Publications
1 publications found
Genes affected
CACNA1H (HGNC:1395): (calcium voltage-gated channel subunit alpha1 H) This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]
CACNA1H Gene-Disease associations (from GenCC):
- hyperaldosteronism, familial, type IVInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- childhood absence epilepsyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- epilepsy, childhood absence, susceptibility to, 6Inheritance: AD Classification: LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.73).
BP6
Variant 16-1220871-C-T is Benign according to our data. Variant chr16-1220871-C-T is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 460181.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.107 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00883 (1345/152250) while in subpopulation AFR AF = 0.0307 (1277/41548). AF 95% confidence interval is 0.0293. There are 28 homozygotes in GnomAd4. There are 653 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High AC in GnomAd4 at 1345 AD gene.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CACNA1H | ENST00000348261.11 | c.6939C>T | p.Pro2313Pro | synonymous_variant | Exon 35 of 35 | 1 | NM_021098.3 | ENSP00000334198.7 | ||
| CACNA1H | ENST00000569107.6 | c.6954C>T | p.Pro2318Pro | synonymous_variant | Exon 34 of 34 | 1 | ENSP00000454990.2 | |||
| CACNA1H | ENST00000711493.1 | c.6924C>T | p.Pro2308Pro | synonymous_variant | Exon 34 of 34 | ENSP00000518778.1 | ||||
| CACNA1H | ENST00000565831.7 | c.6921C>T | p.Pro2307Pro | synonymous_variant | Exon 34 of 34 | 1 | ENSP00000455840.1 | |||
| CACNA1H | ENST00000711450.1 | c.6921C>T | p.Pro2307Pro | synonymous_variant | Exon 35 of 35 | ENSP00000518762.1 | ||||
| CACNA1H | ENST00000564231.6 | c.6906C>T | p.Pro2302Pro | synonymous_variant | Exon 35 of 35 | 1 | ENSP00000457555.2 | |||
| CACNA1H | ENST00000638323.1 | c.6900C>T | p.Pro2300Pro | synonymous_variant | Exon 35 of 35 | 5 | ENSP00000492267.1 | |||
| CACNA1H | ENST00000562079.6 | c.6888C>T | p.Pro2296Pro | synonymous_variant | Exon 34 of 34 | 1 | ENSP00000454581.2 | |||
| CACNA1H | ENST00000711438.1 | c.6882C>T | p.Pro2294Pro | synonymous_variant | Exon 34 of 34 | ENSP00000518754.1 | ||||
| CACNA1H | ENST00000637236.3 | n.*2858C>T | non_coding_transcript_exon_variant | Exon 34 of 34 | 5 | ENSP00000492650.2 | ||||
| CACNA1H | ENST00000639478.1 | n.*1987C>T | non_coding_transcript_exon_variant | Exon 35 of 35 | 5 | ENSP00000491945.1 | ||||
| CACNA1H | ENST00000640028.1 | n.*4757C>T | non_coding_transcript_exon_variant | Exon 35 of 35 | 5 | ENSP00000491488.1 | ||||
| CACNA1H | ENST00000711442.1 | n.*6383C>T | non_coding_transcript_exon_variant | Exon 33 of 34 | ENSP00000518758.1 | |||||
| CACNA1H | ENST00000711448.1 | n.*1880C>T | non_coding_transcript_exon_variant | Exon 36 of 36 | ENSP00000518760.1 | |||||
| CACNA1H | ENST00000711449.1 | n.*1798C>T | non_coding_transcript_exon_variant | Exon 35 of 35 | ENSP00000518761.1 | |||||
| CACNA1H | ENST00000711451.1 | n.*2518C>T | non_coding_transcript_exon_variant | Exon 36 of 36 | ENSP00000518763.1 | |||||
| CACNA1H | ENST00000711452.1 | n.*1606C>T | non_coding_transcript_exon_variant | Exon 36 of 36 | ENSP00000518764.1 | |||||
| CACNA1H | ENST00000711453.1 | n.*1573C>T | non_coding_transcript_exon_variant | Exon 36 of 36 | ENSP00000518765.1 | |||||
| CACNA1H | ENST00000711484.1 | n.*853C>T | non_coding_transcript_exon_variant | Exon 34 of 35 | ENSP00000518773.1 | |||||
| CACNA1H | ENST00000711486.1 | n.6939C>T | non_coding_transcript_exon_variant | Exon 35 of 37 | ENSP00000518775.1 | |||||
| CACNA1H | ENST00000711487.1 | n.6906C>T | non_coding_transcript_exon_variant | Exon 35 of 36 | ENSP00000518776.1 | |||||
| CACNA1H | ENST00000711488.1 | n.*2055C>T | non_coding_transcript_exon_variant | Exon 35 of 35 | ENSP00000518777.1 | |||||
| CACNA1H | ENST00000711482.1 | c.*418C>T | 3_prime_UTR_variant | Exon 36 of 36 | ENSP00000518771.1 | |||||
| CACNA1H | ENST00000711485.1 | c.*418C>T | 3_prime_UTR_variant | Exon 35 of 35 | ENSP00000518774.1 | |||||
| CACNA1H | ENST00000711455.1 | c.*418C>T | 3_prime_UTR_variant | Exon 36 of 36 | ENSP00000518768.1 | |||||
| CACNA1H | ENST00000711483.1 | c.*853C>T | 3_prime_UTR_variant | Exon 35 of 35 | ENSP00000518772.1 | |||||
| CACNA1H | ENST00000711456.1 | c.*853C>T | 3_prime_UTR_variant | Exon 34 of 34 | ENSP00000518769.1 | |||||
| CACNA1H | ENST00000637236.3 | n.*2858C>T | 3_prime_UTR_variant | Exon 34 of 34 | 5 | ENSP00000492650.2 | ||||
| CACNA1H | ENST00000639478.1 | n.*1987C>T | 3_prime_UTR_variant | Exon 35 of 35 | 5 | ENSP00000491945.1 | ||||
| CACNA1H | ENST00000640028.1 | n.*4757C>T | 3_prime_UTR_variant | Exon 35 of 35 | 5 | ENSP00000491488.1 | ||||
| CACNA1H | ENST00000711442.1 | n.*6383C>T | 3_prime_UTR_variant | Exon 33 of 34 | ENSP00000518758.1 | |||||
| CACNA1H | ENST00000711448.1 | n.*1880C>T | 3_prime_UTR_variant | Exon 36 of 36 | ENSP00000518760.1 | |||||
| CACNA1H | ENST00000711449.1 | n.*1798C>T | 3_prime_UTR_variant | Exon 35 of 35 | ENSP00000518761.1 | |||||
| CACNA1H | ENST00000711451.1 | n.*2518C>T | 3_prime_UTR_variant | Exon 36 of 36 | ENSP00000518763.1 | |||||
| CACNA1H | ENST00000711452.1 | n.*1606C>T | 3_prime_UTR_variant | Exon 36 of 36 | ENSP00000518764.1 | |||||
| CACNA1H | ENST00000711453.1 | n.*1573C>T | 3_prime_UTR_variant | Exon 36 of 36 | ENSP00000518765.1 | |||||
| CACNA1H | ENST00000711484.1 | n.*853C>T | 3_prime_UTR_variant | Exon 34 of 35 | ENSP00000518773.1 | |||||
| CACNA1H | ENST00000711488.1 | n.*2055C>T | 3_prime_UTR_variant | Exon 35 of 35 | ENSP00000518777.1 | |||||
| CACNA1H | ENST00000621827.2 | n.6121+818C>T | intron_variant | Intron 35 of 36 | 6 | ENSP00000518766.1 |
Frequencies
GnomAD3 genomes AF: 0.00884 AC: 1345AN: 152132Hom.: 27 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
1345
AN:
152132
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.00231 AC: 573AN: 248342 AF XY: 0.00185 show subpopulations
GnomAD2 exomes
AF:
AC:
573
AN:
248342
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000971 AC: 1418AN: 1460444Hom.: 20 Cov.: 34 AF XY: 0.000837 AC XY: 608AN XY: 726522 show subpopulations
GnomAD4 exome
AF:
AC:
1418
AN:
1460444
Hom.:
Cov.:
34
AF XY:
AC XY:
608
AN XY:
726522
show subpopulations
African (AFR)
AF:
AC:
1088
AN:
33478
American (AMR)
AF:
AC:
90
AN:
44720
Ashkenazi Jewish (ASJ)
AF:
AC:
30
AN:
26128
East Asian (EAS)
AF:
AC:
2
AN:
39700
South Asian (SAS)
AF:
AC:
2
AN:
86254
European-Finnish (FIN)
AF:
AC:
0
AN:
52246
Middle Eastern (MID)
AF:
AC:
7
AN:
5766
European-Non Finnish (NFE)
AF:
AC:
78
AN:
1111798
Other (OTH)
AF:
AC:
121
AN:
60354
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.477
Heterozygous variant carriers
0
82
164
247
329
411
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
36
72
108
144
180
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.00883 AC: 1345AN: 152250Hom.: 28 Cov.: 33 AF XY: 0.00877 AC XY: 653AN XY: 74432 show subpopulations
GnomAD4 genome
AF:
AC:
1345
AN:
152250
Hom.:
Cov.:
33
AF XY:
AC XY:
653
AN XY:
74432
show subpopulations
African (AFR)
AF:
AC:
1277
AN:
41548
American (AMR)
AF:
AC:
38
AN:
15304
Ashkenazi Jewish (ASJ)
AF:
AC:
1
AN:
3472
East Asian (EAS)
AF:
AC:
0
AN:
5162
South Asian (SAS)
AF:
AC:
1
AN:
4820
European-Finnish (FIN)
AF:
AC:
0
AN:
10620
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
12
AN:
68008
Other (OTH)
AF:
AC:
16
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.498
Heterozygous variant carriers
0
66
131
197
262
328
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
16
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
Jan 26, 2020
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
not specified Benign:1
Jun 05, 2024
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Epilepsy, childhood absence, susceptibility to, 6;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Jul 21, 2021
Fulgent Genetics, Fulgent Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.